Bioanalytical CRO business development has a narrower signal set than full-service CRO selling, and treating it like the general case is why most tracked-account lists produce nothing. A two-person BD team does not need every trial event in their therapeutic areas. They need the four or five events that actually precede a bioanalytical scope, and permission to ignore the rest.
One such team, cancelling a contact database subscription this autumn, described the problem precisely: they had plenty of names and no idea which of them were about to need assay work.
Here is the short list worth watching, and the longer list worth skipping.
PK and bioequivalence study starts
This is the core signal. A pharmacokinetics or bioequivalence study registering is the most direct public indicator that bioanalytical work has been scoped or is about to be.
The useful detail is in the study record rather than the headline. Look at the design, the sampling schedule and whether the sponsor has run this type of study before. A generic manufacturer running its fifteenth bioequivalence study has a lab it uses. A specialty pharma running its first has a decision to make.
First-in-human
A first-in-human study is the moment a company's analytical requirements become real and permanent. Before it, the work is preclinical and often handled by whoever did the discovery work. After it, there is a regulated bioanalytical programme that will run for years.
It is also the point at which a sponsor is most open to a new vendor, because for many of them it is the first time they have had to choose one deliberately.
Biosimilar programmes
Biosimilar development carries an unusually heavy analytical burden: comparability, immunogenicity and PK similarity work, all of it regulated and much of it outsourced.
Biosimilar programmes are also easier to spot than most, because the reference product is named and the development path is standardised. If you have immunogenicity capability, this is the segment where it is most clearly differentiating.
Financing and S-1 filings as budget signals
Study registrations tell you work exists. Financing tells you it is funded.
| Signal | What it tells you | How to use it |
|---|---|---|
| Series A or B close | Budget exists for the next phase of work | Write within weeks, while scoping is live |
| Crossover or pre-IPO round | Company is scaling toward late-phase | Larger, longer programmes being planned |
| S-1 or equivalent filing | Full pipeline and planned studies disclosed | The richest public document on a sponsor's next two years |
| Grant award | Specific, often small, funded scope | Useful for academic-adjacent and small-cap sponsors |
The S-1 is the one most BD teams skip and the one that repays reading. It sets out planned studies, risk factors and pipeline detail with a specificity no press release will match.
See Salesmotion on a real account
Book a 15-minute demo and see how your team saves hours on account research.
What to ignore
This matters as much as the list above, because a two-person team's real constraint is attention.
General M&A and leadership churn, unless the change is in clinical pharmacology or development. A new chief financial officer does not change your addressable work.
Phase 3 initiations at large pharma. The analytical vendor was selected years earlier and is embedded. This is the single largest category of interesting-looking, unactionable signal.
Conference attendance. It tells you someone will be in a room. It does not tell you they have a scope to place, and building a prospecting motion on it produces polite conversations and no pipeline.
Anything that does not name a molecule or a study. If you cannot connect the signal to a specific programme, you cannot write a message that sounds like you did the work.
Who to write to
Not the chief executive. At a company small enough for the chief executive to be reachable, they are not making bioanalytical vendor decisions, and at a company large enough for the decision to matter, they will not read it.
Write to clinical pharmacology, bioanalytical leads, and the director or associate director layer in development. These are the people who write scopes and shortlist vendors. They are also, in our experience, considerably more responsive than the executive layer, because they are being written to less and the message is more relevant to their week.
One-to-one, not sequences
The economics here favour quality. A bioanalytical CRO does not need four hundred conversations a quarter. It needs fifteen of the right ones.
That changes what good outreach looks like. A sequence is what you send when you do not know why you are writing. When you do know, one message that references the specific study, the specific molecule and a relevant piece of your own experience outperforms a cadence by a wide margin, and it does not burn the account if the timing turns out to be wrong.
Teams that consolidate this research see the time back somewhere useful. Guild Education's reps recovered six hours per week each once the research step stopped being manual, and that is a general-market number rather than a life-sciences one, but the mechanism is identical: the saving comes from not rebuilding context for every account.
Frequently asked questions
How early can you see a bioanalytical need? Usually at first trial registration for the relevant study type, and sometimes earlier through hiring and financing. Preclinical coverage is partial, so if a sponsor has registered nothing and announced nothing, assume the trail is thin.
Can I search for bioequivalence studies specifically? Not as free text. There is no keyword search across trial records; the search box matches company names and domains. You reach the same place by filtering on therapeutic area, phase and modality, then reviewing the study detail on the accounts that come back.
Do you cover small private sponsors? Where they have registered a trial or filed publicly, yes. Small private companies that have done neither are the genuine coverage gap, and we would rather say that than have you discover it after signing.
Is two people enough to work this properly? Yes, if the list is narrow. The failure mode for small teams is a tracked list of four hundred accounts that nobody reviews. Eighty accounts reviewed weekly beats four hundred reviewed never.
If you want to see which sponsors in your therapeutic areas have PK or bioequivalence work starting, that is a thirty-minute conversation on real records rather than a pitch. See how it works for bioanalytical BD.
